BACKGROUND: Molecular monitoring of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors is essential for therapeutic stratification. Inter-laboratory reproducibility is, therefore, a crucial issue which requires standardization and strict alignment of BCR-ABL1 values to the international scale. An automated cartridge-based assay (Xpert BCR-ABL Monitor(™), Cepheid) had been proposed as a robust alternative to non-automated assays. This study aimed to compare inter-laboratory reproducibility of automated and non-automated quantification, the possibility of converting automated results to the international scale, and the potential economic impact of automation. DESIGN AND METHODS: One hundred and eighteen blood samples from chronic myeloid leukemia patients treated with tyrosine kinase inhibitors were prospectively analyzed in two laboratories using both automated and non-automated assays. The economic evaluation involved a micro-costing study and average costs were assessed as a function of sample throughput. RESULTS: Automated assays achieved similar inter-laboratory reproducibility to highly standardized non-automated assays and a short delay (≤6 h) between sampling and blood lysis had a positive impact on inter-laboratory reproducibility. Reporting automated BCR-ABL1 ratios on the international scale was possible using a specific conversion factor which may vary with batches. Cost assessment showed that automated assays could be relevant for annual activity levels below 300 since average costs were lower than those of the non-automated assays. CONCLUSIONS: The Xpert BCR-ABL Monitor(™) assay could be appropriately used in a near-patient setting for routine quantification of e13/e14-a2 transcripts, preferably in partnership with a regional reference laboratory. However, its prognostic impact relative to non-automated quantification remains to be tested prospectively within appropriate clinical trials.
BACKGROUND: Molecular monitoring of chronic myeloid leukemiapatients treated with tyrosine kinase inhibitors is essential for therapeutic stratification. Inter-laboratory reproducibility is, therefore, a crucial issue which requires standardization and strict alignment of BCR-ABL1 values to the international scale. An automated cartridge-based assay (Xpert BCR-ABL Monitor(™), Cepheid) had been proposed as a robust alternative to non-automated assays. This study aimed to compare inter-laboratory reproducibility of automated and non-automated quantification, the possibility of converting automated results to the international scale, and the potential economic impact of automation. DESIGN AND METHODS: One hundred and eighteen blood samples from chronic myeloid leukemiapatients treated with tyrosine kinase inhibitors were prospectively analyzed in two laboratories using both automated and non-automated assays. The economic evaluation involved a micro-costing study and average costs were assessed as a function of sample throughput. RESULTS: Automated assays achieved similar inter-laboratory reproducibility to highly standardized non-automated assays and a short delay (≤6 h) between sampling and blood lysis had a positive impact on inter-laboratory reproducibility. Reporting automated BCR-ABL1 ratios on the international scale was possible using a specific conversion factor which may vary with batches. Cost assessment showed that automated assays could be relevant for annual activity levels below 300 since average costs were lower than those of the non-automated assays. CONCLUSIONS: The Xpert BCR-ABL Monitor(™) assay could be appropriately used in a near-patient setting for routine quantification of e13/e14-a2 transcripts, preferably in partnership with a regional reference laboratory. However, its prognostic impact relative to non-automated quantification remains to be tested prospectively within appropriate clinical trials.
Authors: S Branford; N C P Cross; A Hochhaus; J Radich; G Saglio; J Kaeda; J Goldman; T Hughes Journal: Leukemia Date: 2006-09-14 Impact factor: 11.528
Authors: Zsolt Jobbagy; Reuel van Atta; Kathleen M Murphy; James R Eshleman; Christopher D Gocke Journal: J Mol Diagn Date: 2007-04 Impact factor: 5.568
Authors: Michele Baccarani; Giuseppe Saglio; John Goldman; Andreas Hochhaus; Bengt Simonsson; Frederick Appelbaum; Jane Apperley; Francisco Cervantes; Jorge Cortes; Michael Deininger; Alois Gratwohl; François Guilhot; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Dietger Niederwieser; Richard Silver; Rudiger Hehlmann Journal: Blood Date: 2006-05-18 Impact factor: 22.113
Authors: Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson Journal: N Engl J Med Date: 2006-12-07 Impact factor: 91.245
Authors: N Bossard; M Velten; L Remontet; A Belot; N Maarouf; A M Bouvier; A V Guizard; B Tretarre; G Launoy; M Colonna; A Danzon; F Molinie; X Troussard; N Bourdon-Raverdy; P M Carli; A Jaffré; C Bessaguet; E Sauleau; C Schvartz; P Arveux; M Maynadié; P Grosclaude; J Estève; J Faivre Journal: Eur J Cancer Date: 2006-11-03 Impact factor: 9.162
Authors: Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman Journal: Blood Date: 2006-03-07 Impact factor: 22.113
Authors: Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich Journal: N Engl J Med Date: 2003-10-09 Impact factor: 91.245
Authors: Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Angelo M Carella; Susan Branford; Michael Deininger; Francois X Mahon; Giuseppe Saglio; Anna Eiring; Jamshid Khorashad; Thomas O'Hare; John M Goldman Journal: Haematologica Date: 2013-08 Impact factor: 9.941
Authors: Anoop Enjeti; Neil Granter; Asma Ashraf; Linda Fletcher; Susan Branford; Philip Rowlings; Susan Dooley Journal: Pathology Date: 2015-10 Impact factor: 5.306
Authors: Valentín García-Gutiérrez; María T Gómez-Casares; José M Puerta; Juan M Alonso-Domínguez; Santiago Osorio; Juan C Hernández-Boluda; Rosa Collado; María J Ramírez; Fátima Ibáñez; María L Martín; Juan D Rodríguez-Gambarte; Carolina Martínez-Laperche; Montse Gómez; Dolly V Fiallo; Sara Redondo; Alicia Rodríguez; Concepción Ruiz-Nuño; Juan L Steegmann; Antonio Jiménez-Velasco Journal: PLoS One Date: 2017-03-09 Impact factor: 3.240
Authors: Nader I Al-Dewik; Hisham M Morsi; Muthanna M Samara; Rola S Ghasoub; Cinquea C Gnanam; Subi K Bhaskaran; Abdulqadir J Nashwan; Rana M Al-Jurf; Mohamed A Ismail; Mohammed M AlSharshani; Ali A AlSayab; Tawfeg I Ben-Omran; Rani B Khatib; Mohamed A Yassin Journal: Clin Med Insights Oncol Date: 2016-10-02